/AI Therapeutics
Invite

Pending to review

Not sure yet

Interested

Not interested

Showing 104 companies

Get more companies

Download list

Company
Fit assessment
Description
Subspaces
Tags
HQ Location
Founded
Employees
Total Funding Raised
Last Funding Event
Received on
Top picks for your space

Meliora Therapeutics leverages machine learning to discover new drug mechanisms and expand therapeutic options, optimizing the drug discovery process.

Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications.
  • Drug Discovery Optimization
Light Search
San Francisco (United States)202111 - 50$11.00MSeed, $11.00M, September 29, 2022
8 months ago

DeepThink Health leverages machine learning to discover patterns and expand therapeutics, while effectively analyzing genomic data.

DeepThink Health has developed a precision intelligence platform that collects, structures, organizes and curates genomic, clinical and lifestyle patient data, and then turns it into actionable intelligence. Its technology platform transforms real-world data into intelligence using DeepThink's advanced analytics, artificial intelligence (AI), predictive modeling, natural language processing and other machine learning tools. This intelligence is used by clinicians, researchers and others to improve patient outcomes, lower institutional costs, and make novel discoveries in the advancement of healthcare. DeepThink Health's innovative team has decades of experience in clinical workflows, data interoperability, big data analytics and artificial intelligence.
  • Genomic Data Analysis
Light Search
Richmond (United States)201811 - 50NA
8 months ago

Converger.ai leverages machine learning and data analytics to discover patterns in genetics and expand therapeutic approaches for disease prevention and treatment.

We are a biotechnology company that uses novel analytics to unlock the secrets of human genetic diversity, helping prevent, diagnose and treat disease.
  • Genomic Data Analysis
Light Search
Johannesburg (South Africa)20231 - 10$205.13KPre-Seed, $200.00K, June 20, 2023
8 months ago

AliveX effectively utilizes machine learning for pattern discovery and therapeutic expansion, with a strong focus on biomarker identification.

Application of artificial intelligence, multi-omics data, and digital disease models to enable the next era of target & biomarker R&D.
  • Biomarker Identification
Light Search
Zürich (Switzerland)201951 - 200Seed, June 22, 2021
8 months ago

BioAI Health effectively utilizes machine learning for pattern discovery and therapeutic expansion, focusing on biomarker identification to enhance personalized medicine.

BioAI Health is a biotech company that uses AI to improve disease diagnosis and predict patient response to therapy. Its platform technology integrates complex data sets from translational studies and clinical trials. It has the capability to develop machine learning models on multi-omic data that can help predict patient response to therapy and drug resistance. The company was founded in 2020 and is based in Goffstown, New Hampshire.
  • Biomarker Identification
Light Search
Goffstown (United States)202011 - 50$3.50MSeed, $500.00K, April 9, 2024
8 months ago

Pure Functionals effectively leverages machine learning and genomic data analysis to enhance clinical decision-making and expand therapeutic options.

Developer of a genomic-based artificial intelligence platform designed to offer bespoke health alternatives, as well as provide insight and precision health analysis for benefit of clinical trials. The company's platform offers insights that will be used to initiate clinical trials as well as consult with existing clinical trials in order to improve efficiency and effectiveness, enabling patients to enhance personalized care by improving clinical decision making.
  • Genomic Data Analysis
Light Search
Amsterdam (Netherlands)20201 - 10Seed, January 1, 2023
8 months ago

Biodesix leverages machine learning and multi-technology approaches to enhance therapeutic options and identify biomarkers, driving personalized medicine in lung cancer diagnostics.

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring, and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.
  • Biomarker Identification
Light Search
Broomfield (United States)200551 - 200$517.27MPost-IPO Equity, $55.00M, April 5, 2024
8 months ago

Biotx.ai leverages machine learning for pattern discovery and therapeutic expansion, while also focusing on biomarker identification for precision medicine.

Biotx.ai delivers next-generation biomarkers as a basis for decision support in precision medicine.
  • Biomarker Identification
Light Search
Berlin (Germany)201711 - 50Convertible Note, April 5, 2023
8 months ago

INNOPLEXUS effectively leverages machine learning to discover patterns and expand therapeutics, while also focusing on biomarker identification for personalized medicine.

At INNOPLEXUS we are helping organisations move to continuous decision-making by generating broader, deeper and faster insights from structured and unstructured private and public data leveraging cutting-edge, patented Artificial Intelligence, Blockchain and advanced analytics technologies. We aim to transform batch decision making in enterprises into a empowered, inspired and faster continuum.   We focus on industries that need to constantly evaluate and improve their efficiency, reduce cost and mitigate risk to keep up with the changing business environment - like global banking, life sciences, and pharmaceutical companies.   In addition to strengthening research efforts, we work to help healthcare organizations leverage technologies to expedite drug development process across all stages - preclinical, clinical, regulatory and commercial. Whether a drug developer is seeking existing research, a medical researcher is searching for alternative treatments, or a practitioner is attempting to find data on a particular disease - increasing access to relevant information removes roadblocks to discovery and fuels rapid growth.   Our Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions are helping Fortune 500 companies drive business outcomes. We automate the collection, curation, aggregation and analysis, of billions of data points from thousands of data sources, using machine learning, network analysis, ontologies, computer vision and entity normalization.   Founded in 2015, INNOPLEXUS AG is headquartered in Eschborn Germany with offices in Pune, India, and Hoboken, USA.
  • Biomarker Identification
Light Search
Eschborn (Germany)2011201 - 500Series C, April 24, 2019
8 months ago

NashBio effectively leverages machine learning and pattern discovery to advance the development of personalized therapeutics and diagnostics.

Operator of a clinical big data, genomics and medical imaging company intended to accelerate the R&D activity of partners in the biopharmaceutical, diagnostics, and AI industries. The company harnesses extensive genomic and bioinformatics resources for drug and diagnostics discovery and development, from a comprehensive genetic database linked to de-identified medical records of longitudinal clinical data to provide clinical insight, resources, and expertise to a wide range of R&D challenges.
  • Genomic Data Analysis
Light Search
Nashville (United States)201811 - 50NA
8 months ago

ATOM leverages machine learning and data-driven modeling to enhance drug discovery, focusing on developing new therapeutics and optimizing the drug design process.

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients.
  • Drug Discovery Optimization
Light Search
San Francisco (United States)201711 - 50NA
8 months ago

Cobiomic Bioscience leverages machine learning and bioinformatics to enhance biomarker identification and expand therapeutic options, ultimately improving patient care.

Cobiomic Bioscience SL focuses on personalized medicine by bridging basic research and clinical practice. The company offers innovative solutions for biomarker identification in various biofluids such as serum, plasma, and urine. Utilizing dual antibody recognition, Cobiomic ensures high specificity in its diagnostic processes. As a biotech spin-off of UCO/IMIBIC, it supports advancements in diagnostics and treatment outcomes, contributing significantly to the field of precision medicine.
  • Biomarker Identification
Light Search
Córdoba (Spain)20161 - 10NA
8 months ago

Pharmaeconomica effectively leverages machine learning and AI to discover new drug candidates, adapt to various therapeutic areas, and optimize the drug discovery process.

Operator of an AI-enhanced physics-based drug discovery company headquartered in Oostende, Belgium. The company discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates, and combines artificial intelligence, computational chemistry, and peptide science to accelerate therapeutic compound discovery, streamline hit identification, and optimize leads.
  • Drug Discovery Optimization
Light Search
Oostende (Belgium)20121 - 10NA
8 months ago

Owkin effectively utilizes machine learning to discover patterns, expand therapeutics, and identify biomarkers, enhancing personalized medicine.

Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. They use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
  • Biomarker Identification
Light Search
New York (United States)2016201 - 500$304.10MSeries B, $50.00M, June 8, 2022
8 months ago

Frontier Medicines effectively leverages machine learning to discover new patterns in protein interactions and expand therapeutic options, optimizing the drug discovery process.

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines. Its platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins that make them accessible to small-molecule drug discovery and development.
  • Drug Discovery Optimization
Light Search
San Francisco (United States)201851 - 200$255.50MSeries C, $20.00M, June 25, 2024
8 months ago

Vium leverages machine learning to discover patterns and identify biomarkers, facilitating the advancement of new therapeutics in preclinical research.

Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
  • Biomarker Identification
Light Search
San Mateo (United States)201351 - 200$53.94MAcquired, July 2020
8 months ago

The USC Big Data Health Science Center leverages machine learning for innovative research, discovering patterns and expanding therapeutic approaches, while also focusing on biomarker identification.

The University of South Carolina (USC) Big Data Health Science Center (BDHSC), an interdisciplinary enterprise and one of the USC Excellence Initiatives established in 2019, promotes and supports big data health science research through capacity development, academic training, professional development, community engagement, and methodological advancement. Its five content cores (Artificial Intelligence for Sensing and Diagnosis, Electronic Health Records, Genomics, Geospatial, and Social Media) and two functional hubs (Business/Entrepreneurship and Technology) embody interdisciplinary collaboration and foster cutting-edge research and discovery. Our mission is to be an innovation-driven enterprise that can facilitate and accelerate a sustained, high-caliber transformation of the USC into a global leader in big data health science.
  • Biomarker Identification
Light Search
United States11 - 50NA
8 months ago

MNM leverages machine learning for pattern discovery and the development of new therapeutics, while also focusing on biomarker identification to enhance personalized medicine.

MNM is a scientific start-up created by an interdisciplinary group of enthusiasts. We are a multi-specialist team of experts from geneticists, to molecular biologists, bioinformaticians and AI specialists. We combine next-generation AI with the most advanced genomic approaches (whole genome and multiomics data) to save the lives of cancer patients through predictive modeling and drug target identification.
  • Biomarker Identification
Light Search
Cambridge (United States)201811 - 50$3.29MSeed, $2.44M, October 20, 2020
8 months ago

Bioada leverages machine learning for pattern discovery and aims to expand therapeutics through innovative biomarker and drug discovery solutions.

Developer of AI-powered biomarker and drug discovery solutions designed to revolutionize EMR software and unlock new frontiers in biomarker and drug discovery. The company offers AI-powered biomarker and drug discovery solutions, enabling customers to make breakthroughs in biomarker and drug discovery that were once thought to be impossible.
  • Biomarker Identification
Light Search
Toronto (Canada)20211 - 10NA
8 months ago

Intelligent OMICS leverages machine learning to discover patterns and expand therapeutic options, while also identifying biomarkers for personalized medicine.

Intelligent OMICS is a translational company that converts big data into biological intelligence.
  • Biomarker Identification
Light Search
Nottingham (United Kingdom)20091 - 10NA
8 months ago

OntoChem leverages machine learning and pattern discovery to enhance therapeutic development and identify biomarkers, showcasing their innovative approach in the life sciences.

OntoChem is a tool and algorithm developer that aims to add value to customers by assisting them in navigating the complex information world. The tools and algorithms developed by the company enable users to apply semantic search solutions for pharmaceutical, material sciences, and technology-driven businesses.
  • Biomarker Identification
Light Search
Halle (Germany)201511 - 50Acquired, June 2023
8 months ago

Pheiron leverages machine learning to discover patterns and develop targeted therapeutics, while also focusing on biomarker identification for personalized medicine.

Pheiron provides a scalable, secure, and interoperable platform for deep data-driven health management. The company focuses on improving the probability of success in drug development by leveraging causal insights on targets and populations. Pheiron uses AI to map multimodal data to diseases, aiming to enhance the understanding of diseases and inform decision-making in drug development. The platform also supports large-scale exome sequence analysis to identify sex- and age-specific factors in health management.
  • Biomarker Identification
Light Search
Berlin (Germany)20231 - 10NA
8 months ago

IMVARIA leverages machine learning to enhance patient outcomes through novel pattern discovery and the expansion of therapeutics, focusing on digital biomarker identification.

IMVARIA is advancing noninvasive AI biomarkers for better patient lives. We bring artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases. IMVARIA serves Fibresolve -- the first AI diagnostic tool in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Fibresolve is an FDA Breakthrough Device and is authorized by the FDA to serve as an adjunctive, non-invasive diagnostic tool for patients with suspected ILD and IPF. Beyond ILD and IPF, IMVARIA is developing AI biomarkers in multiple areas including oncology, pulmonology, immunology, and more.
  • Biomarker Identification
Light Search
Berkeley (United States)201911 - 50Seed, April 30, 2020
8 months ago

The company effectively leverages machine learning for biomarker discovery and therapeutic expansion, demonstrating a strong fit in the healthcare innovation space.

Promise Bio is focused on pioneering precision medicine by utilizing epiproteomic analysis to understand autoimmune diseases. The company employs a cloud-based AI platform to perform comprehensive analyses of standard mass-spectrometry data, revealing insights into protein modifications that affect disease mechanisms.
  • Biomarker Identification
Light Search
Tel Aviv (Israel)202311 - 50$8.30MGrant, December 16, 2024
8 months ago

Talon Biomarkers leverages machine learning for data analysis, discovers patterns in immune cell responses, and enhances therapeutic strategies through biomarker identification.

Developer of a biomarker discovery engine designed for precision medicine and immunotherapy success. The company's services include consultation and support, data analytics, immune profiling, and biomarker discovery services, thereby providing comprehensive immune analysis services and delivering insights that advance understanding and transform patient care.
  • Biomarker Identification
Light Search
Hanover (United States)20211 - 10NA
8 months ago